Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.
about
Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectivesDevelopment of 99mTc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer.Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysisSalivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status.Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancerThe Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy.Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?Usefulness of traditional serum biomarkers for management of breast cancer patients.Circulating tumour cells and cell-free DNA as tools for managing breast cancer.Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.Accurate sensitivity of quantum dots for detection of HER2 expression in breast cancer cells and tissues.HER2-positive gastric cancer identified by serum HER2: A case report.Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients.Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer.Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4).Ultra-low fouling methylimidazolium modified surfaces for the detection of HER2 in breast cancer cell lysates.Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK).Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients.Is "liquid biopsy" useful for assessing HER2 status in gastric cancer?
P2860
Q28077666-B4D0B6AE-4D1A-41C2-85C4-EEFC4A867DA7Q33649880-4FA77D9D-F071-4240-8AED-8C3EC1C45EB5Q33688767-D5CC4F72-9B45-4721-AA56-6680A60E260EQ33927261-C9B8FEB9-6579-4785-B742-307B4A496EC6Q34411112-96C04E87-ABA9-4E16-96FB-D3C89A4E45E9Q36092023-20858AEB-5BFB-4F35-A6D8-19BEBE670C8BQ37218987-F68234A5-7DB8-4DCF-805D-30EECBA09F88Q37375636-180BFA4B-D7F4-4024-8CDF-17C183C3B2BAQ38109808-17E6704A-8D04-4064-9850-19E88F9C4582Q38859024-C3B1E4E0-5892-483B-9F7D-90549E5A9B98Q39232309-CE751277-52DF-479C-B18A-319A6895B402Q41821055-B09DA6DE-E5A2-4392-A5F5-D3F78CF98E7AQ44056799-F0981A55-045A-48A2-9E1F-86F400C00A35Q49787807-87812FAB-E515-4D05-8B67-34D9F184AF06Q50921156-688542D0-4001-4B7F-A1AE-AAA877E3EDA8Q50969937-B4D89A66-6972-4604-BD8E-E83F67E05836Q53212668-B388A8FA-F3F7-4386-953A-0C9E1CFC293FQ53223448-13597BE7-4BCF-4740-B932-FDF31164EF68Q53232564-B74DBE43-A85B-4C7F-9DCD-368C552CD00CQ54352853-2AD627A7-6620-490D-8C24-EC753FAB8A96
P2860
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.
@en
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.
@nl
type
label
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.
@en
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.
@nl
prefLabel
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.
@en
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.
@nl
P1433
P1476
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.
@en
P2093
Brian Leyland-Jones
Brian R Smith
P304
P356
10.1016/S1470-2045(10)70297-7
P577
2011-03-01T00:00:00Z